TITLE

Intravitreal enzyme may improve BRVO

AUTHOR(S)
Hasson, Matt; Preston, Courtney
PUB. DATE
February 2011
SOURCE
Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a study which found that autologous plasmin enzyme intravitreal injection may reduce macular edema and improve visual acuity in people with branch retinal vein occlusion (BRVO).
ACCESSION #
86439020

 

Related Articles

  • Drug promising for BRVO. Charters, Lynda // Ophthalmology Times;3/1/2010, Vol. 35 Issue 5, p48 

    The article offers information on a research conducted on the use of ranibizumab for treating macular edema in patients with branch retinal vein occlusion (BRVO) in Baltimore, Maryland. It states that the medical trial on BRVO was of 12 months and was carried out at 13 locations in the U.S....

  • Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion. Yeo Jue Byun; Mi In Roh; Sung Chul Lee; Hyoung Jun Koh // Graefe's Archive of Clinical & Experimental Ophthalmology;Jul2010, Vol. 248 Issue 7, p963 

    To compare visual outcomes after intravitreal triamcinolone acetonide (IVTA) injection and intravitreal bevacizumab (IVB) administration for treatment of macular edema associated with branch retinal vein occlusion (BRVO). A retrospective comparative case series of 134 consecutive patients that...

  • Intravitreal plasmin effectively treats DME patients unresponsive to other treatments.  // Ocular Surgery News Europe/Asia-Pacific Edition;Dec2008, Vol. 19 Issue 12, p1 

    The article reports on the efficacy of intravitreal plasmin for the treatment of diabetic macular edema (DME) that were unresponsive to laser or other injections. Findings of research on the effectiveness of intravitreal plasmin injections were presented by Patricia Udaondo at the 2008 American...

  • Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Kashani, Shahram // Current Medical Literature: Ophthalmology;2014, Vol. 24 Issue 3, p94 

    The article reviews a research study published in the March 17, 2014 issue of the journal "Ophthalmology" which observed long-term disease control in eyes with non-infectious uveitis following treatment with repeat dexamethasone implants for management of cystoid macular edema. Research findings...

  • Short-Term Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Obstruction and Diabetic Macular Edema. Byeon, Suk H.; Kwon, Young A.; Hyun-Sub Oh; Min Kim; Kwon, Oh W. // Journal of Ocular Pharmacology & Therapeutics;Aug2007, Vol. 23 Issue 4, p387 

    Objective: The aim of this study was to identify the short-term effect, safety, and durability of intravitreally injected bevacizumab in patients with macular edema (ME) caused by retinal vein obstruction (RVO) and diabetic macular edema (DME). Methods: We retrospectively evaluated 39 eyes of 36...

  • Anti-VEGF agent may be an option for nonresponsive CME. Bechtel, Bryan // Ocular Surgery News;8/10/2009, Vol. 27 Issue 15, p9 

    The article discusses a study which examined the use of intravitreal bevacizumab in treating patients who are nonresponsive to previous treatment for cystoid macular edema (CME) following cataract surgery. CME is a common complication of cataract surgery. Results of the study showed that...

  • Intravitreal Ranibizumab in the Treatment of Cystoid Macular Edema Associated With Retinitis Pigmentosa. Artunay, Ozgur; Yuzbasioglu, Erdal; Rasier, Rifat; Sengul, Alper; Bahcecioglu, Halil // Journal of Ocular Pharmacology & Therapeutics;Dec2009, Vol. 25 Issue 6, p545 

    Purpose: To report and evaluate the anatomic, clinical, and visual acuity response after intravitreal ranibizumab (IVR) injection in patients with cystoid macular edema (CME) due to retinitis pigmentosa (RP). Methods: This study included 30 eyes of 30 patients with RP who had persistent CME at...

  • Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Kashani, Shahram // Current Medical Literature: Ophthalmology;2015, Vol. 25 Issue 3, p88 

    The article discusses a 2015 study by R. Sophie et al and published in the journal "Ophthalmology" that identified baseline predictors of best corrected visual acuity and central foveal thickness in patients with diabetic macular edema after 24 months of treatment with either intravenous drug...

  • Intravitreal Triamcinolone in Diabetic Retinopathy. Abraldes, Maximino J.; Fernández, Maribel; Gómez-Ulla, Francisco // Current Diabetes Reviews;2009, Vol. 5 Issue 1, p18 

    Diabetic macular edema is an important cause of visual loss in the developed world and may frequently lead to irreversible changes in visual acuity. The Early Treatment Diabetic Retinopathy Study showed a significant benefit in using focal laser photocoagulation for the treatment of macular...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics